Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases

Abstract

Although the putative therapeutic options for patients with systemic lupus erythematosus (SLE) are steadily increasing, refractory disease is indeed a major challenge to many clinicians and patients. The proteasome inhibitor bortezomib – approved for the treatment of multiple myeloma since the beginning of this century – was recently reported successful in twelve cases of refractory SLE by German colleagues. Herein, we describe two Swedish SLE cases with refractory renal and pulmonary manifestations that were rescued by bortezomib as induction of remission followed by monthly doses of belimumab. The patients were carefully monitored with regard to disease activity and renal function. Anti-dsDNA and anti-C1q antibodies, complement proteins and lymphocyte subsets were analysed in consecutive samples. In December 2016, the patients had been in clinical remission post bortezomib administration for a period of 28 and 22 months, respectively. Potential benefits of using belimumab as maintenance therapy to prevent regeneration of autoreactive B cell clones are discussed.

Keywords

Anti-DNA antibodies renal lupus systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Lightstone

. Minimising steroids in lupus nephritis – will B cell depletion pave the way? Lupus 2013; 22: 390–399.

Houssiau

Vasconcelos

D’Cruz

et al.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121–2131.

Alexander

Thiel

Rosen

et al.

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113: 214–223.

Hoyer

Moser

Hauser

et al.

Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577–1584.

Benson

Dillon

Castigli

et al.

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008; 180: 3655–3659.

Neubert

Meister

Moser

et al.

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748–755.

Alexander

Sarfert

Klotsche

et al.

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74: 1474–1478.

Rath

Zwerina

Oppl

Nell-Duxneuner

. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015; 165: 28–35.

Obeng

Carlson

Gutman

Harrington

Jr Lee

Boise

. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907–4916.

10.

Khodadadi

Cheng

Alexander

et al.

Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS One 2015; 10: e0135081–e0135081.

11.

Parodis

Axelsson

Gunnarsson

. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus 2013; 22: 372–380.

12.

Taddeo

Khodadadi

Voigt

et al.

Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 2015; 17: 39–39.